Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials

Table 2

Patients and lesion characteristics of the included studies.

Study	Group	Target vessel, %				RVD, mm	MLD, mm	DS%, %	LVEF, %	UA, %	SA/SI, %	ISR Mehran classification, %
		LAD	LCX	RCA	VB							I	II	III-IV
DARE, 2018 [5]	DCB	41.0%	0.0%	37.0%	0.7%	2.56 ± 0.43	0.77 ± 0.33	69.7 ± 11.8	NR	44%	NR	51%	32%	17%
	EES	39.0%	0.7%	35.0%	1.4%	2.59 ± 0.54	0.79 ± 0.35	69.3 ± 12.5	NR	42%	NR	53%	34%	13%
RESTORE, 2018 [4]	DCB	55.8%	15.1%	27.9%	1.2%	2.85 ± 0.50	0.63 ± 0.40	77 ± 17	59.4% ± 8.4%	45.30%	41.80%	67.20%	14.90%	17.90%
	EES	60.5%	12.8%	24.4%	0.0%	3.06 ± 0.45	0.63 ± 0.42	79 ± 13	59.9% ± 7.8%	38.40%	45.40%	66.20%	19.10%	14.70%
RIBS IV, 2015 [9, 12]	DCB	37.0%	22.0%	39.0%	2.0%	2.64 ± 0.60	1.02 ± 0.40	61 ± 14	58% ± 13%	40%	60%	63%	34%	3%
	EES	39.0%	23.0%	34.0%	3.0%	2.64 ± 0.60	0.93 ± 0.40	65 ± 13	59% ±1 2%	45%	56%	64%	28%	8%
RIBS V, 2014 [11, 14]	DCB	50.0%	18.0%	28.0%	4.0%	2.58 ± 0.50	0.79 ± 0.40	69 ± 17	58% ± 12%	52%	48%	40%	47%	13%
	EES	46.0%	22.0%	29.0%	3.0%	2.55 ± 0.50	0.75 ± 0.40	72 ± 15	59% ± 11%	51%	49%	36%	45%	19%
SEDUCE, 2014 [10]	DCB	24.0%	20.0%	52.0%	4.0%	3.00 ± 0.48	0.98 ± 0.60	67.7 ± 18.4	NR	20%	76%	32%	52%	16%
	EES	44.0%	28.0%	24.0%	0.0%	2.85 ± 0.44	0.57 ± 0.37	79.4 ± 13.5	NR	20%	76%	36%	40%	24%
TIS, 2016 [6, 12]	DCB	47.3%	NR	29.7%	1.4%	2.64 ± 0.47	0.92 ± 0.45	71.8 ± 13.9	49.7% ± 12.0%	NR	64.70%	40.54%	45.95%	13.52%
	EES	54.1%	NR	29.7%	2.7%	2.66 ± 0.45	0.79 ± 0.48	78.0 ± 13.4	49.6% ± 11.4%	NR	63.20%	28.38%	47.30%	24.32%

Data are shown as percentage or mean ± standard deviation. DCB, drug-coated balloons; EES, everolimus-eluting stents; LAD, anterior descending branch; LCX, left circumflex artery; RCA, right coronary artery; VB, vein bypass; RVD, reference vessel diameter; MLD, minimum lumen diameter; DS, diameter stenosis; LVEF, left ventricular ejection fraction; UA, unstable angina; SA/SI, stable angina/silent ischemia; ISR, in-stent stenosis; NR, not reported.